Influence of Calcium-Sensing Receptor Gene on Urinary Calcium Excretion in Stone-Forming Patients

GIUSEPPE VEZZOLI,* ANNALISA TANINI,† LUIGI FERRUCCI,‡ LAURA SOLDATI,§ CRISTIANA BIANCHIN,* FRANCESCO FRANCESCHELLI,† CECILIA MALENTACCHI,‡ BERARDINO PORFIRIO,§ DONATELLA ADAMO,§ ANNALISA TERRANEGRA,§ ALBERTO FALCHETTI,† DANIELE CUSI,§ GIUSEPPE BIANCHI,* and MARIA LUISA BRANDI†

*Division of Nephrology Dialysis and Hypertension, Postgraduate School of Nephrology, Ateneo Vita e Salute, IRCCS San Raffaele Hospital, Milan, Italy; †Department of Internal Medicine, University of Florence, Florence, Italy; ‡Laboratory of Clinical Epidemiology, INRCA Geriatric Department, Florence, Italy; §Department of Biomedical Sciences and Technology, University of Milan, Milan, Italy; and ¶Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Abstract. Calcium-sensing receptor (CaSR) is a plasma membrane protein that regulates parathyroid hormone (PTH) secretion by parathyroid cells and Ca reabsorption by kidney tubular cells (1–3). It is activated by the increase of extracellular concentration of Ca ions, which bind to the large extracellular N-terminal domain of the CaSR molecule (1,2). CaSR exerts its cellular activity through the stimulation of a G protein by its intracellular tail (2), which leads to the inhibition of PTH production (3) and tubular Ca reabsorption (2,4). In addition, CaSR influences intestinal Ca absorption (5), bone remodeling (6,7), and even nervous transmission (8).

Inactivating mutations of CASR gene account for disorders characterized by hypocalcemia and hypercalcemia due to the altered control of PTH release and tubular Ca reabsorption: heterozygotes develop benign familial hypocalciuric hypercalcaemia, whereas homozygotes are affected by severe neonatal hyperparathyroidism (9,10). Through opposite mechanisms, mutations enhancing CaSR activity lead to disorders characterized by hypocalcemia and hypercalciuria (11).

Three clustered single nucleotide polymorphisms (SNP), causing nonconservative amino acid changes, have been described on exon 7, encoding the intracellular domain of CaSR (12,13). The most common SNP consists of the substitution of a guanine with a thymine at codon 986, leading to the Ala986Ser variant (12,13). The other two SNP are less frequent: an adenine/guanine substitution at codon 990 determines the Arg990Gly variant; a cytosine/guanine substitution at codon 1011 determines the Gln1011Glu variant. The functional effects of these amino acid changes are yet unknown, but a slight increase of plasma Ca concentrations, not associated with symptoms, was found in healthy subjects carrying the 986Ser allele (12).

Studies in humans (9) and in canine tubular cells (4) showed an inhibitory effect of CaSR on cellular Ca transport, suggesting that CaSR plays a key-role in the regulation of Ca excretion. In keeping with these observations, CASR gene has been...
considered a candidate for idiopathic hypercalciuria (14), a familial disorder predisposing to Ca kidney stones and characterized by increased Ca excretion in the presence of normal Ca concentrations in plasma (15,16). This view has been contrasted by a study in Ca stone-forming French-Canadian sibling pairs, finding no linkage between idiopathic hypercalciuria and CASR gene locus (17). However, even though CASR gene may not be a major determinant in idiopathic hypercalciuria, its polymorphisms may influence tubular Ca reabsorption capacity. Therefore, in the present study, the association of urinary Ca excretion with CASR gene SNP was evaluated in an Italian population of healthy subjects and of hypercalciuric and normocalciuric Ca stone formers.

Materials and Methods

Patients

Ninety-seven normocalciuric stone formers (65 male patients and 32 female patients; weight, 69 ± 1.2 kg; age, 45 ± 1.5 yr), 134 hypercalciuric stone formers (78 male patients and 56 female patients; weight, 69 ± 1.1 kg; age, 47 ± 1.1 yr), and 101 normocalciuric healthy controls (58 male patients and 43 female patients; weight, 72 ± 1.2 kg; age, 46 ± 1.2 yr) were included in the study. These subjects were white and were characterized by no polymorphic variants or by the presence of a polymorphic variant at one single CASR exon 7 SNP. According to these criteria, six individuals (two healthy subjects, one normocalciuric, and three hypercalciuric stone formers), who were double heterozygotes for two CASR exon 7 SNP, were not included among the subjects enrolled for the study.

Stone formers were recruited at their first visit at the Outpatient Stone Clinic of San Raffaele Hospital in Milan, Italy. To be included in the study, stone formers had to have produced at least one Ca kidney stone and their plasma creatinine, sodium, potassium, and Ca concentrations had to be normal. All of them had to be able to lower urinary pH under 5.5. Stones present in patient urinary tract had to have diameter smaller than 5 mm. None of them had to have obstructive nephropathy or urinary tract dilatation, evaluated by echographic examination. Most of the patients (n = 150; 65%) were addressed to the clinic after lithotripsy and were studied at least 3 mo after lithotriptic treatment. The hospital’s protocol does not include any pharmacologic treatment for kidney stones immediately after lithotripsy, but only dietary counseling (increase of water intake). The other patients (n = 81; 35%) were sent to the Outpatient Clinic by physicians before starting any kind of treatment. In no case was a patient studied if he or she took any treatment for kidney stones (thiazide, citrate, or others) for at least 3 mo before the study. No patient had diseases other than kidney stone, and none took any long-term medications.

Healthy subjects were selected from the population recruited for the InCHIANTI study, an epidemiologic survey conducted in Greve and Bagno a Ripoli, two little towns near Florence. They were selected according to the following criteria: absence of hypercalciuria, age between 20 and 60 yr, no clinical diagnosis of hypertension, diabetes, dyslipidemia, stroke, coronary heart disease, kidney stones, and no treatment with drugs affecting Ca metabolism, like Ca salts or long-term medications.

The study agrees with the indications of the Helsinki Declaration and was approved by San Raffaele Hospital Ethical Committee. All subjects gave informed consent to the study and genomic analysis.

Phenotyping

Total plasma concentration of Ca and 24-h Ca excretion were determined in healthy subjects and in stone-forming patients. In stone formers, 24-h excretion of phosphates and sodium, serum phosphate, plasma creatinine, and PTH and intestinal absorption of strontium were also measured. Intact PTH was determined by immunoradiometric assay (Nichols Institute). Strontium was used as a surrogate marker to assess intestinal Ca absorption. Intestinal strontium absorption was determined after an oral load, as described previously (20). Strontium (30.2 µmol of Sr per kg of body weight) was administered to patients in distilled water solution as chloride salt after overnight fast. Blood samples were drawn 60 min after strontium load ingestion, and strontium concentrations were measured in serum by atomic absorption spectrophotometer (Perkin-Elmer 4000; Perkin-Elmer, Norwalk, CT). Ion absorption was calculated as the incremental area (above baseline) under the serum strontium concentration-time curve, using the trapezoid method (mnmol · L⁻¹ · min).

Genotyping

Genomic DNA was isolated from peripheral blood cells by standard procedures. Mutation screening was carried out by denaturing gradient gel electrophoresis (DGGE) in hypercalciuric patients. The entire CASR coding sequence (exons 2 to 7) was amplified by the PCR. DNA amplification primers for each exon were designed on the basis of Pearse et al. and Vigouroux et al. (11,21); moreover, one of the two primers used in each PCR had the proper 5’ end GC-tail to create a high melting temperature domain.

Samples were run on the Bio-Rad DCode denaturing gel electrophoresis system for mutation detection (Bio-Rad, Hercules, CA). The denaturing conditions were from 20% to 80%, whereas acrylamide concentration ranged from 6% to 10% depending on fragment length. Electrophoresis was performed at a constant temperature of 60°C at 120 V for 12 h. Gels were stained with ethidium bromide and were photographed with Kodak Digital Camera (Eastman Kodak, Rochester, NY).

Part of exon 7 of CASR gene, which comprises 3 SNP (G/T at codon 986, A/G at codon 990, and C/G at codon 1011), were evaluated by PCR amplification and direct sequencing. PCR was carried out using primers 5’tcggaggtctacttttgaggacggtc3’ and 5’tgcagacctgtttttaagaggactttgc3’, sequenced that flank the polymorphic site giving an amplimer of 206 bp. Purified PCR products served as template for the sequence reaction, which was performed using a ready reaction mix (ABI PRISM Big-Dye Terminator Cycle Sequencing Ready Reaction Kit, Applied Biosystems, Foster City, CA) and the same forward primer as for PCR. Sequence products were generated during 25 cycles of the following steps: 15 s at 96°C, 10 s at 50°C, and 2 min at 60°C. Unincorporated dye terminators were removed by ethanol/sodium acetate precipitation. Afterward, dyed samples were denatured in 20 µl of Template Suppression Reagent (TSR, Applied Biosystems) at 95°C for 10 min and cooled on ice for 15 min. The ABI PRISM 310 Genetic Analyzer (Applied Biosystems) was used for capillary electrophoresis. All sequences were analyzed for comparison using resident software.

Four haplotypes were defined on the basis of exon 7 SNP of CASR gene (Table 1): they were respectively characterized by the most common sequence (haplotype 1) or by the presence of one single polymorphic variant, respectively at 986 (haplotype 2), 990 (haplo-
According to these criteria, six double heterozygotes at CASR exon 7 SNP were not considered, as already mentioned. Participants in the study were divided into four groups according to their haplotypes: group 1 was composed by Ala986, Azg990, and Gen1011 homozygotes; group 2 was composed by 986Ser homozygotes and Ala986Ser heterozygotes; group 3 was composed by 990Gly homozygotes and Arg990Gly heterozygotes; group 4 was composed by Gln1011Glu heterozygotes (Table 1).

### Statistical Analyses

Distribution of CASR genotypes was compared in normocalciuric and hypercalciuric stone formers and healthy subjects by multinomial logistic regression. Relative risk to be hypercalciuric was estimated by the calculation of the odds ratio (OR) and its 95% confidence interval (95% CI).

Quantitative variables were reported in the text as mean ± SE. Differences of the means were tested by t test or one-way ANOVA with Scheffe’s post-hoc multiple comparisons test.

Dependence of Ca excretion or plasma Ca concentration on CASR haplotypes was evaluated in stone formers by multiple regression analysis. To take into account the effect of possible confounders, we used a two-step multiple regression model in which the confounders were entered at the first step and CASR haplotypes at the second step. Statistical analyses were conducted at the α = 0.05 level and were two-tailed. All analyses were performed using the SPSS 10 statistical package (SPSS Inc., Chicago, IL).

### Results

#### Frequency of CaSR Polymorphisms

Preliminary analysis by DDGE showed no abnormal mobility pattern of CASR gene in either hypercalciuric and normocalciuric stone formers, but the already described shifts of exon 7 (data not shown). Genotype frequencies at polymorphic sites did not deviate from those expected according to Hardy-Weinberg equilibrium in both healthy subjects and stone formers. Furthermore, no linkage disequilibrium was observed among the three SNP (data not shown).

In the whole population, haplotype 1 represented the most frequent sequence of CASR gene exon 7. According to these criteria, six double heterozygotes at CASR exon 7 SNP were not considered, as already mentioned. Participants in the study were divided into four groups according to their haplotypes: group 1 was composed by Ala986, Azg990, and Gen1011 homozygotes; group 2 was composed by 986Ser homozygotes and Ala986Ser heterozygotes; group 3 was composed by 990Gly homozygotes and Arg990Gly heterozygotes; group 4 was composed by Gln1011Glu heterozygotes (Table 1).

#### Table 1.
Patients and haplotypes

<table>
<thead>
<tr>
<th>Haplotype</th>
<th>n</th>
<th>Base Change</th>
<th>Amino Acid Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>986</td>
<td>990</td>
</tr>
<tr>
<td>Group 1</td>
<td>186</td>
<td>GCC</td>
<td>AGG</td>
</tr>
<tr>
<td>Haplotype 1</td>
<td>GCC</td>
<td>AGG</td>
<td>CAG</td>
</tr>
<tr>
<td>Group 2</td>
<td>101</td>
<td>TCC</td>
<td>AGG</td>
</tr>
<tr>
<td>Haplotype 1</td>
<td>GCC</td>
<td>AGG</td>
<td>CAG</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>TCC</td>
<td>AGG</td>
</tr>
<tr>
<td>Group 3</td>
<td>15</td>
<td>GCC</td>
<td>GGG</td>
</tr>
<tr>
<td>Haplotype 1</td>
<td>GCC</td>
<td>GGG</td>
<td>CAG</td>
</tr>
<tr>
<td>Group 4</td>
<td>12</td>
<td>GCC</td>
<td>AGG</td>
</tr>
<tr>
<td>Haplotype 1</td>
<td>GCC</td>
<td>AGG</td>
<td>CAG</td>
</tr>
</tbody>
</table>

### Table 2.
Distribution of individuals with different CASR haplotypes was compared in healthy subjects and normocalciuric or hypercalciuric stone formers

<table>
<thead>
<tr>
<th>Haplotype</th>
<th>n</th>
<th>Base Change</th>
<th>Amino Acid Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>986</td>
<td>990</td>
</tr>
<tr>
<td>Group 1</td>
<td>53 (52.5%)</td>
<td>74 (55.2%)</td>
<td>59 (60.8%)</td>
</tr>
<tr>
<td>Group 2</td>
<td>44 (43.6%)</td>
<td>43 (32.1%)</td>
<td>31 (32%)</td>
</tr>
<tr>
<td>Group 3</td>
<td>1 (1%)</td>
<td>13 (9.7%)</td>
<td>2 (2.1%)</td>
</tr>
<tr>
<td>Group 4</td>
<td>3 (3%)</td>
<td>4 (3%)</td>
<td>5 (5.2%)</td>
</tr>
</tbody>
</table>

* Group composition is displayed in Table 1.
Association between Haplotypes and Phenotypes in the Whole Population

The quantitative variables were compared in individuals with different haplotypes. At first, healthy subjects and stone formers were considered together (Table 4). Ca excretion was higher in individuals carrying haplotype 3 (n = 16; 9.18 ± 0.95 mmol/24 h) than in those not carrying haplotype 3 (n = 316; 6.16 ± 0.19 mmol/24 h; P = 0.0005, t test). Although one-way ANOVA showed no significant difference in plasma Ca concentration between individual groups (Table 4), it was slightly higher in individuals carrying the haplotype 2 (n = 118; 2.37 ± 0.01 mmol/L) than in those not carrying haplotype 2 (n = 214; 2.35 ± 0.01 mmol/L; P = 0.047, t test). This difference was particularly marked in the 17 homozygotes for haplotype 2 (2.41 ± 0.02 mmol/L; P = 0.02 versus individuals not carrying haplotype 2, t test), whereas their Ca excretion was not increased (5.46 ± 0.89 mmol/24 h).

Association between Haplotypes and Phenotypes in Stone Formers

Also when stone formers were considered alone (Table 5), Ca excretion remained significantly higher in haplotype 3 than in haplotype 1 patients or when compared with all patients not carrying haplotype 3 (n = 216; 7.23 ± 0.23 mmol/24 h; P = 0.007, t test). Stone formers carrying haplotype 2 had marginally significant higher plasma Ca concentration than those not carrying haplotype 2 (n = 157; 2.35 ± 0.01 mmol/L; P = 0.05, t test). A further increase of plasma Ca was observed in stone formers homozygous for haplotype 2 (n = 8; 2.41 ± 0.01), whereas urinary Ca excretion (7.06 ± 1.71 mmol/24 h) was not different from that of other groups.

### Table 3. Results of multinomial logistic regression in hypercalciuric and normocalciuric stone formers, with healthy controls as the reference population in the analysis

<table>
<thead>
<tr>
<th></th>
<th>Odds Ratio</th>
<th>95% CI</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypercalciuric stone formers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>haplotype 1</td>
<td>1.40</td>
<td>0.98 to 1.99</td>
<td>0.06</td>
</tr>
<tr>
<td>haplotype 2</td>
<td>0.98</td>
<td>0.64 to 1.49</td>
<td>0.92</td>
</tr>
<tr>
<td>haplotype 3</td>
<td>13.00</td>
<td>1.7 to 99.4</td>
<td>0.01</td>
</tr>
<tr>
<td>haplotype 4</td>
<td>1.33</td>
<td>0.3 to 5.96</td>
<td>0.71</td>
</tr>
<tr>
<td>Normocalciuric stone formers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>haplotype 1</td>
<td>1.11</td>
<td>0.77 to 1.61</td>
<td>0.57</td>
</tr>
<tr>
<td>haplotype 2</td>
<td>0.71</td>
<td>0.45 to 1.12</td>
<td>0.14</td>
</tr>
<tr>
<td>haplotype 3</td>
<td>2.00</td>
<td>0.18 to 22.06</td>
<td>0.57</td>
</tr>
<tr>
<td>haplotype 4</td>
<td>1.67</td>
<td>0.40 to 6.97</td>
<td>0.48</td>
</tr>
</tbody>
</table>

Forty-three hypercalciuric stone formers carried haplotype 2; their plasma Ca concentration (2.39 ± 0.01 mmol/L) and Ca excretion (10.38 ± 0.51 mmol/24 h) were higher than in the other 91 hypercalciuric stone formers (2.35 ± 0.01 mmol/L [P = 0.026] and 9.13 ± 0.26 mmol/24 h [P = 0.016, t test], respectively). Only three homozygotes for haplotype 2 were detected among hypercalciuric stone formers (plasma Ca: 2.43 ± 0.02 mmol/L; Ca excretion 11.97 ± 2.54 mmol/24 h).

Multiple Regression

The capacity of CaSR haplotypes to explain variance of Ca excretion was analyzed by multiple regression in stone formers. Independent variables were entered in the regression model in two subsequent steps. In the first step, potential confounders of the association between haplotype and Ca excretion were entered in the model: namely, they were body weight, age, plasma Ca, plasma PTH, serum phosphate, plasma creatinine, intestinal strontium absorption, and sodium excretion. In the second step, haplotype 2 or haplotype 3 was entered and added to the other independent variables.

Sodium excretion, body weight, plasma creatinine, and enteral absorption of strontium associated with Ca excretion (r² = 0.284; F = 6.1; P = 0.0001). Haplotype 3 significantly improved the percentage of explained variance by 12.6% (cumulative r² = 0.326; F = 6.54; P = 0.0001; r² change = 0.041; F change = 7.5, P = 0.007). Haplotype 2 did not contribute to the variance of Ca excretion (r² change = 0.007; F change = 1.21; P = 0.27). Regression analysis for plasma Ca was performed with the same model and the same independent variables used for calciuria analysis, but including calciuria at the place of plasma Ca concentrations. No variables other than haplotype 2 showed significant association with the plasma Ca concentration (cumulative r² = 0.101; F = 1.52; P = 0.15; r² change = 0.04; F change=5.58, P = 0.02).

Discussion

Several pieces of evidence indicate that CaSR plays an important role in the regulation of tubular Ca reabsorption (1,2,4). In keeping with these studies, CASR gene has been proposed as a candidate gene for idiopathic hypercalciuria (14). However, testing this hypothesis, Petrucci et al. (17) found no linkage of idiopathic hypercalcemia and Ca nephrolithiasis with CASR gene locus when using an affected sib-pair approach in a French-Canadian population. Indeed, DGGGE analysis of the entire coding sequence of CASR gene failed to detect abnormal mobility patterns suggestive for mutations in hypercalciuric patients, with the exception of the already known SNP on exon 7 (10). Accordingly, a previous DNA sequencing study found no point mutations of CASR in members of French hypercalciuric families (22).

The functional importance of exon 7 polymorphisms has been suggested by the lower plasma Ca concentration in healthy subjects carrying the allele 986Ser (12) and by the lower plasma PTH level in Japanese uremic patients carrying the allele 990Gly (23). Genetic polymorphisms of CASR exon 7 could account for the phenotype variability of a quantitative multifactorial trait such as Ca excretion. Therefore, in the
Table 4. Urinary Ca excretion and plasma Ca concentration in stone formers and healthy controls considered together and divided according to the haplotypes of CASR gene

<table>
<thead>
<tr>
<th></th>
<th>Group 1 b</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Group 4</th>
<th>F</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>186</td>
<td>118</td>
<td>16</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma Ca (mmol/L)</td>
<td>2.35 ± 0.01</td>
<td>2.37 ± 0.01</td>
<td>2.35 ± 0.02</td>
<td>2.38 ± 0.02</td>
<td>1.67</td>
<td>0.17</td>
</tr>
<tr>
<td>Urinary Ca excretion (mmol/24 h) a</td>
<td>6.05 ± 0.22</td>
<td>6.44 ± 0.35</td>
<td>9.18 ± 0.95</td>
<td>5.05 ± 0.86</td>
<td>4.86</td>
<td>0.003</td>
</tr>
</tbody>
</table>

a P < 0.05, group 3 versus each other haplotype group by Scheffe post hoc test. No significant difference among groups 1, 2, and 4.

Table 5. Values of phenotypes were compared in stone formers with different haplotypes of CASR gene

<table>
<thead>
<tr>
<th></th>
<th>Group 1 b</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Group 4</th>
<th>F</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>133</td>
<td>74</td>
<td>15</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma Ca (mmol/L)</td>
<td>2.35 ± 0.01</td>
<td>2.38 ± 0.01</td>
<td>2.35 ± 0.02</td>
<td>2.38 ± 0.03</td>
<td>1.43</td>
<td>0.24</td>
</tr>
<tr>
<td>Urinary Ca excretion (mmol/24 h) a</td>
<td>6.91 ± 0.26</td>
<td>7.96 ± 0.46</td>
<td>9.68 ± 0.87</td>
<td>6.00 ± 0.91</td>
<td>4.46</td>
<td>0.005</td>
</tr>
<tr>
<td>PTH (pg/ml)</td>
<td>35 ± 1.6</td>
<td>37 ± 2.3</td>
<td>40 ± 4.3</td>
<td>36 ± 6.0</td>
<td>0.84</td>
<td>0.72</td>
</tr>
<tr>
<td>Plasma creatinine (mg/dl)</td>
<td>0.9 ± 0.02</td>
<td>0.90 ± 0.02</td>
<td>0.94 ± 0.04</td>
<td>1.0 ± 0.07</td>
<td>0.07</td>
<td>0.82</td>
</tr>
<tr>
<td>Serum phosphate (mmol/L)</td>
<td>1.04 ± 0.02</td>
<td>1.02 ± 0.03</td>
<td>1.07 ± 0.07</td>
<td>1.02 ± 0.05</td>
<td>0.31</td>
<td>0.82</td>
</tr>
<tr>
<td>Urinary phosphate excretion (mmol/24 h)</td>
<td>27.01 ± 0.84</td>
<td>28.41 ± 1.2</td>
<td>27.73 ± 2.01</td>
<td>27.28 ± 3.48</td>
<td>0.32</td>
<td>0.81</td>
</tr>
<tr>
<td>Urinary sodium (mmol/24 h)</td>
<td>171 ± 6.8</td>
<td>171 ± 8.9</td>
<td>169 ± 16.7</td>
<td>208 ± 24.8</td>
<td>0.63</td>
<td>0.59</td>
</tr>
<tr>
<td>Enteral Sr absorption (mmol · L⁻¹ · min)</td>
<td>10.1 ± 0.34</td>
<td>11.5 ± 0.63</td>
<td>11.9 ± 0.93</td>
<td>1.07 ± 0.32</td>
<td>1.53</td>
<td>0.21</td>
</tr>
</tbody>
</table>

a P < 0.05 group 3 versus group 1 by Scheffe post hoc test. No other significant differences among groups.
b Group composition is displayed in Table 1.

present study, we evaluated the distribution of these SNP in healthy subjects and in a large cohort of stone formers, comprising a high number of hypercalciuric patients. We found that a polymorphic variant of the CASR gene was associated with the increase of Ca excretion and could contribute to the Ca excretion variability in our patients.

Genotypes of exon 7 variants were distributed according to the Hardy-Weinberg equilibrium both in stone formers and healthy subjects. Ala986Ser was the most frequent SNP, and its frequency in our populations was close to that previously reported in other white populations (12,13,25,26). Haplotype 3 was significantly more frequent in hypercalciuric stone formers than in normocalciuric patients or healthy subjects, so that it increased the probability to be hypercalciuric for the carriers. This suggests that Arg990Gly polymorphism affects Ca excretion, the 990Gly allele predisposing to idiopathic hypercalciuria. Indeed, haplotype 3 explains a small but significant proportion of Ca excretion variance in stone formers. It equals 12.6% of the explained variance and 4.1% of the total variance of urinary Ca excretion, in agreement with its multifactorial nature (27,28). The low explained variance excludes CASR as a major gene for idiopathic hypercalciuria (24,29).

Therefore, CASR gene is one of the genetic components modulating Ca excretion. The minor contribution of CASR gene to Ca excretion could explain why no linkage was shown between urinary Ca excretion and CASR locus in a study on French-Canadian stone-forming sib-pairs (17). However, the different genetic background in Canadian and Italian populations could modify the weight of CASR in Ca excretion determination (24,30). Furthermore, that study could be underpowered for the small genotype relative risk we observed (29). To reduce the influence of unknown genetic components or unevenness with controls, we compared hypercalciuric stone formers with two normocalciuric groups: healthy subjects and stone formers (30). Patients and controls were recruited in different areas: Lombardy and Tuscany. Previous studies with several polymorphic markers failed to disclose genetic heterogeneity among Italian regions, except for Sardinia (31). Therefore, our samples of healthy subjects and patients appear to be representative of Italian population, excluding the risk of genetic stratification.

The activation of CaSR by extracellular Ca inhibits tubular Ca reabsorption acting directly on ion transport (2,4). We propose that the 990Gly allele increases CaSR sensitivity or response to Ca ions. Accordingly, PTH secretion could be more inhibited by the 990Gly allele, in agreement with previous findings in uremic patients (23).

The contribution of Ala986Ser polymorphism to plasma Ca variance is confirmed in the present study (12). Although not corrected for serum albumin, plasma Ca was slightly but sig-
nificantly higher in individuals carrying 986Ser allele. This association suggests that the inhibitory activity of CaSR on tubular Ca reabsorption and PTH secretion be depressed in subjects carrying haplotype 2 (1). In spite of these effects, the increase of plasma Ca was coupled with elevated Ca excretion in hypercalciuric patients carrying haplotype 2. A possible interpretation of these findings is that the decreased tubular Ca reabsorption, characterizing hypercalciuric patients, could overcome the enhancing effect of haplotype 2 on tubular Ca transport. In addition, the larger glomerular filtration of Ca, associated with increased Ca concentration in blood, could facilitate Ca loss in these patients (1,4). Conversely, in normocalciuric subjects carrying haplotype 2, the increase of filtered Ca could be balanced by the increased reabsorptive capacity.

Previous studies revealed that patients with idiopathic hypercalciuria exhibited a decreased axial and peripheral bone density (32,33), increased bone resorption (34), and histologic features of high bone turnover (35). These findings suggest that an abnormality in bone remodeling could be involved in the features of high bone turnover (35). These findings suggest that the decreased tubular Ca reabsorption, characterizing hypercalciuric patients, could overcome the enhancing effect of haplotype 2 on tubular Ca transport. In addition, the larger glomerular filtration of Ca, associated with increased Ca concentration in blood, could facilitate Ca loss in these patients (1,4). Conversely, in normocalciuric subjects carrying haplotype 2, the increase of filtered Ca could be balanced by the increased reabsorptive capacity.

In conclusion, CAST gene variants on bone reabsorption in idiopathic hypercalciuria.

Enteral absorption of Ca is typically increased in hypercalciuric patients (26) and could be influenced by CaSR as well (5). Its alteration was proposed as the primary event in hypercalciuria (16), but our results do not support any relation among CAST gene polymorphisms and intestinal Ca absorption, tested using strontium as a surrogate marker.

In conclusion, CAST gene could be considered as a component of the genetic background regulating Ca excretion. Arg990Gly polymorphism could produce a gain-of-function for CaSR that could increase Ca excretion and the susceptibility to idiopathic hypercalciuria. Ala986Ser polymorphism appears to affect Ca concentration in blood, possibly through a decrease in CaSR activity, which could cause a further increase of Ca excretion in hypercalciuric patients. Future studies will attempt to evaluate the function of these polymorphisms through in vitro analyses.

Acknowledgments

This study was supported by funds from Ministry of Education, University and Scientific Research (Cofin 1999, protocol No. 9906217489-003) and Research Institute San Raffaele Hospital, Milan, Italy.

References


